Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Invitae to Acquire Genosity to Speed Time to Market of Personalised Oncology Offerings.

Document Cited in Related
Vincent

MANews-(C)2009-2021

US medical genetics company Invitae (NYSE: NVTA) has agreed to acquire life science biotechnology company Genosity Inc. to support mainstream adoption of personalised cancer care and monitoring, the company said.

Under the terms of the agreement, Invitae will acquire Genosity for approximately USD 200m, consisting of USD 120m in cash and approximately USD 80m in shares of Invitae common stock with such stock and cash consideration subject to reduction based upon certain debt and transaction expenses of Genosity determined at closing.

In connection with the transaction, Invitae will grant restricted stock units, having a value of up to USD 15m to certain continuing employees of Genosity.

The acquisition would bring Genosity's specialised capabilities onto the Invitae platform to decentralise Invitae's personalised oncology offerings, including somatic and germline offerings poised to help transform how cancer is diagnosed, treated and monitored.

Invitae is currently developing its Personalised...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT